[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection-reactivation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection-reactivation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100560078","phase-2-atg-individualized-dosing-model-in-urd-pbsct-100560078",false,"NCT06572462","ATG Individualized Dosing Model in URD-PBSCT.","Application of Thymoglobulin (ATG) Individualized Dosing Model in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.","Inclusion Criteria:\n\n1. Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.\n2. HLA-matched unrelated donor\n3. Patient age ≥14 years old and ≤65 years old\n4. ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values\n5. Creatinine ≤ high limit of normal value\n6. No uncontrollable infection or serious mental illness\n7. Physical strength score is 0-2 (ECOG)\n8. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Unrelated donor who is not HLA matched\n2. No indication for allogeneic hematopoietic stem cell transplantation\n3. Patient age \\\u003C14 years old or \\>65 years old\n4. The donor or recipient are pregnant\n5. Suffering from mental illness or other conditions and being unable to proceed as planned","ALL","14 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. A targeted dosing strategy was established based on ATG concentration monitoring and conducted a phase 2 trial to evaluate the safety and efficacy of the dosing strategy in adult unmanipulated haplo-PBSCT, a encouraging result was attained. In this trial, The ATG-targeted dosing strategy was extended to adult unrelated donor allogeneic hematopoietic stem cell transplantation, ATG was administered for 4 days (-5 days to -2 days) during conditioning. The ATG doses on-3 days and- 2days were adjusted by our dosing strategy to achieve the optimal ATG exposure. The primary endpoint was CMV reactivation on +180 days.",[27,28,29],"Cytomegalovirus Infections","Infection Reactivation","Stem Cell Transplant Complications","RECRUITING","2024-11-28",{"date":33,"type":34},"2024-12-03","ACTUAL",{"date":36,"type":34},"2020-12-31",{"date":38,"type":21},"2025-06-30",{"name":40,"class":41},"Chinese PLA General Hospital","OTHER"]